Case reports (12 cases confirmed by Swan) indicate a likely association
Over 13 cases have been observed in France in 2,900 CML patients treated with dasatinib -> suggests that the lowest estimate incidence of dasatinib-associated pulmonary hypertension is approximately 0.45%
Risk Factors
Female Sex
Prior Treatment with Imatinib (Gleevec) (see Imatinib, [[Imatinib]]): imatinib is also a tyrosine kinase inhibitor
Clinical: may occur at any time during treatment
Some cases occurred >12 mo after treatment
Treatment/Prognosis: discontinue drug -> leads to improvement in some cases
Case Series: improvement was observed within 4 mo of drug discontinuation in all but 1 patient (however, after a median follow-up of 9 mo, most patients did not demonstrate complete recovery, and 2 patients died) [MEDLINE]
Other Adverse Effects
xxx
xxx
xxx
References
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukaemia. Leuk Res 2009;33:861–4 [MEDLINE]
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med. 2011 May 23;11:30. doi: 10.1186/1471-2466-11-30 [MEDLINE]
Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Intern Med. 2012;51(17):2337-40 [MEDLINE]
Pulmonary hypertension in patients treated by dasatinib. Circulation 2012;125:2128–37 [MEDLINE]
